Following the first half which was recorded in Japanese, the second half dives deeper into the uniqueness and potential of EditForce’s technology!
Guest: Takashi Ono, President and CEO of EditForce
Host: Priyanka Soni, Senior Associate and Maiko Iinuma, HR at UTEC
◆ Guest Profile
Takashi Ono
Mr. Ono began his career at Sosei Co., Ltd. (now Nxera Pharma Co., Ltd.) in 2002, serving as Manager and then Head of Business Development. In 2009, he joined ITOCHU Corporation as a Project Manager in the Development and Research Department, while concurrently serving as Head of Business Development at Solasia Pharma K.K. He joined EditForce Inc. as Director and COO in 2018, and has served in his current role since March 2019.
◆ About EditForce Inc.
EditForce Inc. is a biotechnology venture company engaged in drug discovery and seed/plant breeding based on nucleic acid (DNA/RNA) manipulation technologies. The company was founded in 2015 by KISCO Ltd. and Professor Takahiro Nakamura of Kyushu University (Associate Professor at the time, currently Professor).In addition to proprietary genome editing, EditForce provides the world’s first “transcriptome editing” tool, enabling RNA manipulation on a genome-wide scale. This pioneering platform is based on engineering technology for PPR (pentatricopeptide repeat) proteins, invented by Professor Nakamura.Originally studied in the context of plant immunity, PPR proteins are capable of recognizing nucleic acid sequences (DNA/RNA). By elucidating this mechanism, EditForce has developed novel genome design and programming tools using PPR proteins, aiming to apply them across pharmaceuticals, agriculture, and other industries.Official Website: https://www.editforce.co.jp/
If you are interested in an investment from UTEC, please contact us via the form below.
https://share.hsforms.com/1_WfJXAagSWmKnsxVxSalXQc3fla
